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Abstract: A single nucleotide polymorphism (SNP) in CYP2C8 (rs1934951), was previously 
identified in a genome-wide association study as a risk factor for the development of osteone-
crosis of the jaw (ONJ) in patients receiving bisphosphonates (BPs) for multiple myeloma. To 
determine if the same SNP is also associated with the development of ONJ in men receiving 
BPs for bone metastases from prostate cancer, we genotyped 100 men with castrate-resistant 
prostate cancer treated with bisphosphonates for bone metastases, 17 of whom developed ONJ. 
Important clinical characteristics, including type and duration of bisphosphonate therapy, were 
consistent among those who developed ONJ and those who did not. We found no significant cor-
relation between the variant allele and the development of ONJ (OR = 0.63, 95% CI: 0.165–2.42, 
P . 0.47). This intronic SNP in CYP2C8 (rs1934951) does not seem to be a risk factor for the 
development of bisphosphonate-related ONJ in men with prostate cancer. It is important to note 
that this is only the second study to investigate the genetics associated with BP-related ONJ and 
the first to do so in men with prostate cancer. More studies are needed to identify genetic risk 
factors that may predict the development of this important clinical condition.
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Introduction
Approximately 90% of men with advanced prostate cancer develop bone metastases.1 
Skeletal metastases can cause serious morbidities, including pathological fracture 
and severe pain.2 In prostate cancer, skeletal complications are often compounded 
by anticancer treatment, particularly androgen deprivation therapy (ADT), which has 
been shown to cause treatment-induced bone loss.2,3 Bisphosphonates (BPs) are potent 
osteoclast inhibitors that have been used to treat various bone diseases, including 
skeletal complications from bone metastases in men with prostate cancer.2–7
Due to their relatively increased rate of bone turnover, the mandible and maxilla 
often contain high levels of BPs.8,9 A high incidence of osteonecrosis of the jaw (ONJ) 
in patients treated with BPs was first reported in 2003.10 Since that time, multiple studies 
have supported the role of bisphosphonates in the development of ONJ.8,11–16 In 2007, 
3 criteria for the diagnosis of bisphosphonate-related ONJ were established: exposed 
bone in the maxillofacial region that remained unhealed for a minimum of 8 weeks, 
exposure to BPs, and no history of radiation therapy in the craniofacial region.17
Because BP-related ONJ was only recently identified, much remains unknown 
about the condition, including the true incidence. The most commonly reported Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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incidence range is 6% to 15% in men with prostate cancer,9 
though other studies have reported slightly higher rates.18,19 
Also, little is known about risk factors for its   development. 
There are some established risk factors, including prior 
dental procedure, especially dental extraction,14,16,20,21 type 
of BP,11,21 and length of BP treatment, with increased treat-
ment duration positively correlated with risk.11,14,16,20,21 
Some studies suggest that concurrent treatments such as 
chemotherapy,14,16 corticosteroids,14,20 and antiangiogenic 
therapy18,22,23 may also increase risk. Other studies have found 
no such correlation.21,24 Therefore, markers that better predict 
the development of ONJ are needed to identify patients who 
are susceptible to the condition, especially in the setting of 
prostate cancer, where men often receive many of these 
therapies concurrently with BPs.
One area that has remained mostly unexplored is the link 
between genetics and bisphosphonate-related ONJ. In the first 
exploration of the genetic risk factors for ONJ, Sarasquete 
et al recently employed a genome-wide association study to 
identify single nucleotide polymorphisms (SNPs) associated 
with the development of this condition in patients with mul-
tiple myeloma receiving BP therapy. This study resulted in 
the identification of an intronic SNP in CYP2C8 as the first 
possible genetic risk factor for developing bisphosphonate-
related ONJ.25 Based on these results, we hypothesized that 
the same SNP may be associated with the development of 
ONJ in men with prostate cancer treated with BPs. To our 
knowledge, we are the first to investigate the genetics behind 
the development of BP-related ONJ in men with prostate 
cancer.
Materials and methods
Patients
We retrospectively genotyped 100 men who received BPs 
for bone metastases from advanced prostate cancer and who 
participated in at least 1 clinical trial at the National Cancer 
Institute (NCI). Patients are derived from participants of 
33 clinical trials taking place at the NCI, and many patients 
underwent multiple clinical trials. All men received zole-
dronic acid (Zometa®; Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, USA). Of these, most patients received 
a standard dose: 4 mg infused over 15 minutes every 3 to 
4 weeks. Four men received multiple BPs, though not con-
currently. The patient who received a combination of BPs 
and developed ONJ was treated with zoledronic acid and 
  alendronate (Fosamax®; Merck & Co., Inc., Whitehouse 
  Station, NJ, USA). Two of the men who received a combi-
nation of BPs and did not develop ONJ received zoledronic 
acid and alendronate, and the third patient received zoledronic 
acid and pamidronate (Aredia®; Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA). In addition to BPs, all 
men had received androgen deprivation therapy, as well as 
some combination of chemotherapy, steroids, and antiangio-
genic therapy, including sorafenib, thalidomide, AZD2171, 
and/or bevacizumab. No men received BPs for the treatment 
of osteoporosis. Data on dental extraction, and oral hygiene 
were not available; however, it is unlikely that a significant 
number of patients with advanced castrate-resistant prostate 
cancer underwent significant dental procedures immediately 
prior to, or during therapy. This study was approved by the 
Internal Review Board of the National Cancer Institute.
genotyping
DNA was extracted from plasma using a QIAamp Ultra-
Sens Virus Kit (Qiagen, Valencia, CA, USA) and stored 
at 4°C. Genotyping was conducted via direct nucleotide 
sequencing at the CYP2C8 locus (G . A transition; 
rs1934951) using nested PCR. The primary PCR primers 
used were F1 5′-ACTACTTCTCCTCACTTCTGGAC-3′ 
and R1 5′-TCAAGGCAGGTAAGGAAAGATCAG-3′. The 
  secondary PCR primers were F2 5′-TCCAAATATCTTT 
GACCCT GGC-3′ and R2 5′-ATGTATCTAGTGGCA 
GAGTTCAG-3′. A 20 µL reaction was prepared for primary 
PCR amplification and a 50 µL reaction was prepared for 
secondary PCR amplification. Each reaction consisted of 
1 × PCR buffer, 2 mmol/L of each of the 4 deoxynucleotide 
triphosphates, 1.5 mmol/L magnesium chloride, 20 mmol/L 
of the forward and reverse primers, 1 unit of Platinum Taq 
DNA polymerase (Invitrogen, Carlsbad, CA, USA), and 
5 µL of template DNA. Primary PCR conditions were 94°C 
for 5 minutes, followed by 20 cycles of 94°C for 30   seconds, 
68°C for 30 seconds, and 72°C for 30 seconds, with a final 
extension step at 72°C for 7 minutes. Secondary PCR 
  conditions were 94°C for 5 minutes, followed by 40 cycles 
of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 
30 seconds, with a final extension step at 72°C for 7 minutes. 
Direct nucleotide sequencing PCR was performed using the 
Big Dye Terminator Cycle Sequencing Ready Reaction kit 
V3.1 on an ABI Prism 3130xl Genetic Analyzer (Applied 
BioSystems, Foster City, CA, USA). The secondary PCR 
primers were also used for sequencing.
Analysis
Statistical analysis was performed using analysis of variance 
and the Chi-squared and Fisher’s exact tests using NCSS 
software (NCSS, Kaysville, Utah, USA) and Microsoft Excel Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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(Microsoft, Redmond, WA, USA). The a priori P value for 
an association was considered to be (P , 0.05).
Results
One hundred men with advanced prostate cancer treated 
with BPs for bone metastases were genotyped for an intronic 
CYP2C8 G . A SNP (rs1934951) previously shown to 
be associated with the development of BP-related ONJ in 
patients with multiple myeloma.25 Patient characteristics, 
including type and duration of BP treatment, are described in 
Table 1, and genotypic and allelic frequencies are presented 
in Table 2 along with ONJ status. All patients received 
  chemotherapy, steroids, and antiangiogenic therapy. Most 
of the patients (94%) received only zoledronic acid, and this 
was consistent among those who developed ONJ and those 
who did not. Although we were unable to determine the exact 
duration of BP treatment for many men, we were able to 
determine in 94% of cases whether the men had received BPs 
for greater than or less than a year. The racial breakdown was 
consistent between the 2 groups (those who developed ONJ 
and those who did not), the majority (approximately 80%) 
being Caucasians. The median age of all men at their initial 
prostate cancer diagnosis was 59 years of age (range: 43–75), 
and this was similar between the 2 groups (Table 1).
Genotypic and allelic frequencies are presented in 
Table 2. All genotypes were found to be in Hardy–Weinberg 
equilibrium. There was no statistically significant relationship 
between the genotype and development of ONJ (P . 0.65), 
and the variant allele did not correlate with the develop-
ment of ONJ (odds ratio = 0.63, 95% confidence interval: 
0.165–2.42, P . 0.47). In fact, of the 3 homozygous variant 
men, none developed ONJ. Finally, there were no associa-
tions between type or duration of BP, race, or age of prostate 
cancer diagnosis and ONJ development (P . 0.40 for all 
characteristics).
Discussion
This study suggests that there is no relationship between the 
development of BP-related ONJ in men with prostate cancer 
and the rs1934951 locus in CYP2C8, a potential risk factor 
previously identified in study of individuals with multiple 
myeloma.25 We were also unable to detect any relationship 
between ONJ development and basic clinical characteristics 
of men with prostate cancer. Our incidence of ONJ (17%), 
while high, was consistent with other studies in similar 
populations.18,19
Because nitrogen-containing BPs (eg, zolendronic acid), 
a group that includes those commonly prescribed for bone 
involvement in patients with cancer, are not metabolized,26 
it is unlikely that this is a strictly pharmacogenetic relation-
ship per se. However, as Sarasquete et al describe, CYP2C8 
is involved in many endogenous pathways, and alterations in 
these pathways could increase a person’s risk of   developing 
ONJ.25 For example, CYP2C8 metabolizes arachidonic acid 
to epoxyeicosatrienoic acids,27 and epoxyeicosatrienoic acids 
are involved in vascular tone and vascular endothelial growth 
factor (VEGF)-activated angiogenesis.28 In addition, BPs have 
antiangiogenic effects in vivo29,30 and have been shown to sup-
press VEGF expression in cultured cells.31 Thus, it is possible 
that accumulation of microtrauma from osteoclast inhibition 
by BPs could be enhanced by insufficient vasculature due to 
both variations in CYP2C8 and impaired angiogenesis from BP 
therapy, thus increasing a person’s risk of developing ONJ.
It is important to note that the effects of the SNP discussed 
here are not known. As an intronic SNP, its effects at the 
protein level are not straightforward; it does not result in an 
amino acid change, and it does not appear to be in a splice 
Table 1 Patient characteristics
BP ONJ All 
n = 100 (+) 
n = 17
(-) 
n = 83
Zoledronic acid 16 (94.1%) 78 (94.0%) 94 (94.0%)
ibandronate 0 (0%) 1 (1.2%) 1 (1.0%)
Pamidronate 0 (0%) 1 (1.2%) 1 (1.0%)
Combination 1 (5.9%) 3 (3.6%) 4 (4.0%)
BP duration
$1 year 15 (88.2%) 63 (75.9%) 78 (78.0%)
,1 year 2 (11.8%) 14 (16.9%) 16 (16.0%)
Unknown 0 (0%) 6 (8.4%) 6 (6.0%)
Race
Caucasian 14 (82.4%) 66 (79.5%) 80 (80.0%)
African American 2 (11.8%) 10 (12.0%) 12 (12.0%)
hispanic 1 (5.9%) 5 (6.0%) 6 (6.0%)
Asian 0 (0%) 2 (2.4%) 2 (2.0%)
Median age at 
diagnosis (range)
60 (48–75) 59 (43–75) 59 (43–75)
Abbreviations: BP, bisphosphonate; OnJ, osteonecrosis of the jaw.
Table 2 genotype frequencies
Genotype at CYP2C8 
rs1934951*
ONJ All 
n = 100 (+) 
n = 17
(-) 
n = 83
gg 14 (82.4%) 62 (74.7%) 76 (76.0%)
gA 3 (17.6%) 18 (21.7%) 21 (21.0%)
AA 0 (0%) 3 (3.6%) 3 (3.0%)
gA and AA combined** 3 (17.6%) 21 (25.3%) 24 (24%)
Notes: *P . 0.05 for all genotypes; **OR = 0.63 (95% Ci: 0.165–2.42), P . 0.47 for 
gg vs gA and AA combined.
Abbreviations: CI, confidence interval; ONJ, osteonecrosis of the jaw; OR, odds 
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site. Even if it does not result in a functional change, it could 
be a marker for another polymorphism. However, HapMap 
(www.hapmap.org, last accessed 1 Dec, 2009) analysis does 
not show any significant linkage, though it may be a marker 
for currently unknown SNPs. Sarasquete et al also suggest 
that intronic SNPs may affect intronic miRNAs but do not 
show that this is the case for the investigated SNP.25
There are several possible reasons why our study did not 
find an association between the CYP2C8 SNP and develop-
ment of ONJ. First, we genotyped men with prostate cancer 
while Sarasquete et al25 genotyped both men and women with 
multiple myeloma, and an individual’s underlying disease 
may influence the development of ONJ.32 It is also possible 
that the SNP identified by Sarasquete et al was a false positive 
despite their stringent statistical testing and identification of 
other SNPs within CYP2C8 that trended toward an asso-
ciation with ONJ though was not statistically significant.25 
We also recognize that there are some limitations to our data. 
We did not initially select our patient cohort to have matched 
controls for our cases of ONJ, though important character-
istics such as race, age of prostate cancer diagnosis, and 
type and duration of BP treatment were consistent between 
those who developed ONJ and those who did not (Table 2). 
Further, though duration of BP treatment is a demonstrated 
risk factor for ONJ development,11,14,16,20,21 we were unable 
to ascertain exact BP-treatment time-course data for many 
patients. Instead we could only determine if a patient had 
received BPs over a time period greater than or less than a 
year. Finally, we were unable to determine if ONJ was more 
or less frequent in individual clinical trails given the relatively 
few patients who developed ONJ, and the large numbers of 
trials from which we obtained patients. Thus, further studies 
carefully examining time-course data are warranted. Finally, 
while all patients received ADT, chemotherapy, steroids, and 
antiangiogenic therapy at some point in their disease course, 
the type and duration of treatment as well as their temporal 
relationship with BP use was heterogeneous. This variation 
may have positively or negatively affected the likelihood of 
the development of ONJ.
To our knowledge, this is only the second study to 
investigate the genetics behind BP-related ONJ and the first 
to do so in men with prostate cancer. Though our retrospec-
tive investigation did not find the same association between 
the CYP2C8 rs1934951 SNP and the development ONJ 
as Sarasquete et al,25 more studies in independent patient 
cohorts are necessary to determine if genetic   polymorphisms 
in CYP2C8 are a risk factor for the development of ONJ. 
As ONJ causes significant morbidity in men with   prostate 
cancer,   identification of genetic variants that may put 
patients at greater risk should continue to be an area of active 
investigation.
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